A Korean Drug Manufacturer Deepens Its U.S. Bet With Local Hiring Push

As pharmaceutical companies place growing emphasis on domestic production, regulatory certainty and supply-chain resilience, competition among contract drug manufacturers in the United States is increasingly being shaped by operational credibility rather than sheer capacity. For CDMOs seeking to win business from global drugmakers, the ability to operate smoothly under U.S. regulatory scrutiny has become a decisive differentiator.

That shift is drawing new international players deeper into the U.S. market. Lotte Biologics, a South Korea–based contract development and manufacturing organization, has begun expanding its U.S. workforce as it works to anchor its global strategy in American operations. Recent job postings indicate the company is recruiting experienced technical staff for its Syracuse Bio Campus in New York, signaling a push to strengthen on-site execution and quality systems rather than relying solely on overseas scale.

Read the full article:
https://guru.today/lotte-biologics-us-hiring-cdmo-expansion/